MCID: END015
MIFTS: 30

Endometrial Adenosquamous Carcinoma

Categories: Cancer diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Endometrial Adenosquamous Carcinoma

MalaCards integrated aliases for Endometrial Adenosquamous Carcinoma:

Name: Endometrial Adenosquamous Carcinoma 12 53 15 73
Adenosquamous Carcinoma of the Endometrium 53
Endometrial Adenosquamous Cell Carcinoma 73
Adenosquamous Carcinoma of Endometrium 12
Endometrial Adenosquamous Cancer 53

Classifications:



External Ids:

Disease Ontology 12 DOID:5631

Summaries for Endometrial Adenosquamous Carcinoma

Disease Ontology : 12 An endometrial carcinoma that derives from squamous cells and gland-like cells.

MalaCards based summary : Endometrial Adenosquamous Carcinoma, also known as adenosquamous carcinoma of the endometrium, is related to adenocarcinoma and adenosquamous carcinoma. An important gene associated with Endometrial Adenosquamous Carcinoma is SERPINA3 (Serpin Family A Member 3), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Lung fibrosis. The drugs Lenograstim and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include lung, bone and breast.

Related Diseases for Endometrial Adenosquamous Carcinoma

Diseases related to Endometrial Adenosquamous Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 11)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 10.2
2 adenosquamous carcinoma 10.1
3 breast cyst 9.9 EGF SERPINA3
4 xanthogranulomatous pyelonephritis 9.9 EGF SERPINA3
5 maxillary cancer 9.9 EGF PLAU
6 breast adenocarcinoma 9.8 EGF PLAU
7 breast disease 9.8 EGF PLAU
8 alzheimer disease 2 9.8 PLAU SERPINA3
9 adamantinoma of long bones 9.8 EGF PLAU
10 lung cancer susceptibility 3 9.7 EGF PLAU
11 prostate cancer 9.5 EGF PLAU SERPINA3

Graphical network of the top 20 diseases related to Endometrial Adenosquamous Carcinoma:



Diseases related to Endometrial Adenosquamous Carcinoma

Symptoms & Phenotypes for Endometrial Adenosquamous Carcinoma

Drugs & Therapeutics for Endometrial Adenosquamous Carcinoma

Drugs for Endometrial Adenosquamous Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 45)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 3,Phase 1 135968-09-1
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
3
Doxorubicin Approved, Investigational Phase 3,Phase 1 23214-92-8 31703
4
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
5
Doxil Approved June 1999 Phase 3,Phase 1 31703
6 Immunologic Factors Phase 3,Phase 2,Phase 1
7 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
8 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
9 Topoisomerase Inhibitors Phase 3,Phase 1
10 Adjuvants, Immunologic Phase 3,Phase 1
11 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
12 Antimitotic Agents Phase 3,Phase 2,Phase 1
13 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
14
Gemcitabine Approved Phase 2 95058-81-4 60750
15
Bevacizumab Approved, Investigational Phase 2 216974-75-3
16
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
17
Medroxyprogesterone acetate Approved, Investigational Phase 2 71-58-9
18
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
19
Everolimus Approved Phase 2 159351-69-6 6442177
20
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
21
Maleic acid Experimental Phase 2 110-16-7 444266
22
Cediranib Investigational Phase 2 288383-20-0 9933475
23
Trebananib Investigational Phase 2 894356-79-7
24 Anti-Infective Agents Phase 2
25 Antiviral Agents Phase 2
26 Antimetabolites Phase 2
27 Antimetabolites, Antineoplastic Phase 2
28 Immunosuppressive Agents Phase 2
29 Protein Kinase Inhibitors Phase 2
30 Angiogenesis Modulating Agents Phase 2
31 Angiogenesis Inhibitors Phase 2
32 Immunoglobulins Phase 2
33 Antibodies, Monoclonal Phase 2
34 Immunoglobulin G Phase 2
35 Antibodies Phase 2
36 Endothelial Growth Factors Phase 2
37 Mitogens Phase 2
38 Contraceptives, Oral Phase 2
39
Medroxyprogesterone Phase 2 520-85-4 10631
40 Antineoplastic Agents, Hormonal Phase 2
41 Contraceptive Agents, Male Phase 2
42 Contraceptive Agents Phase 2
43 Epothilones Phase 2
44 Epothilone B Phase 2
45 Antifungal Agents Phase 2

Interventional clinical trials:

(show all 12)
# Name Status NCT ID Phase Drugs
1 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
2 Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01011933 Phase 2 Selumetinib
3 Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00820898 Phase 2 Gemcitabine Hydrochloride
4 Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer Completed NCT01307631 Phase 2 Akt Inhibitor MK2206
5 Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01132820 Phase 2 Cediranib Maleate
6 Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer Completed NCT01210222 Phase 2
7 Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer Completed NCT01005329 Phase 2 Carboplatin;Cisplatin;Paclitaxel
8 Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus Completed NCT00064025 Phase 2 Medroxyprogesterone
9 Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer Recruiting NCT00492778 Phase 2 Cisplatin
10 Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Active, not recruiting NCT00977574 Phase 2 Carboplatin;Ixabepilone;Paclitaxel;Temsirolimus
11 Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Suspended NCT01935934 Phase 2 Cabozantinib S-malate
12 Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer Completed NCT00575952 Phase 1 Cisplatin;Doxorubicin Hydrochloride;Paclitaxel

Search NIH Clinical Center for Endometrial Adenosquamous Carcinoma

Genetic Tests for Endometrial Adenosquamous Carcinoma

Anatomical Context for Endometrial Adenosquamous Carcinoma

MalaCards organs/tissues related to Endometrial Adenosquamous Carcinoma:

41
Lung, Bone, Breast, Prostate

Publications for Endometrial Adenosquamous Carcinoma

Articles related to Endometrial Adenosquamous Carcinoma:

# Title Authors Year
1
Endometrial adenosquamous carcinoma with osteoclast-like giant cells: immunohistochemistry and histogenesis. ( 15723689 )
2005
2
Paraneoplastic hypercalcemia associated with adenosquamous carcinoma of the endometrium. ( 1989923 )
1991
3
Adenosquamous carcinoma of the endometrium. ( 1002838 )
1976

Variations for Endometrial Adenosquamous Carcinoma

Expression for Endometrial Adenosquamous Carcinoma

Search GEO for disease gene expression data for Endometrial Adenosquamous Carcinoma.

Pathways for Endometrial Adenosquamous Carcinoma

Pathways related to Endometrial Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.21 EGF PLAU SERPINA3
2 10.42 EGF PLAU

GO Terms for Endometrial Adenosquamous Carcinoma

Cellular components related to Endometrial Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.43 EGF PLAU SERPINA3
2 extracellular exosome GO:0070062 9.33 EGF PLAU SERPINA3
3 extracellular space GO:0005615 9.13 EGF PLAU SERPINA3
4 platelet alpha granule lumen GO:0031093 8.62 EGF SERPINA3

Biological processes related to Endometrial Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neutrophil degranulation GO:0043312 9.16 PLAU SERPINA3
2 positive regulation of cell migration GO:0030335 8.96 EGF PLAU
3 platelet degranulation GO:0002576 8.62 EGF SERPINA3

Sources for Endometrial Adenosquamous Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....